Guest guest Posted January 30, 2003 Report Share Posted January 30, 2003 : Wed, 29 Jan 2003 13:10:01 -0500 Annual Tradition ANNUAL TRADITION Health Sciences Institute e-Alert January 29, 2003 ************************************************************** Dear Reader, In an e-Alert dated exactly one year ago today ( " More Bad News About Remicade and Enbrel " 1/29/02), I gave you the latest information on the disturbing side effects of two prescription drugs used to treat rheumatoid arthritis (RA) and Crohn's disease. Back then I said, " Unfortunately, the news gets even worse, " and told you about research that showed both drugs may cause nerve damage that can lead to MS and other central nervous system disorders A year later, unfortunately, the news continues to get even worse. ----------------------------- Adding to the list ----------------------------- Earlier this month Reuters Health reported that two large clinical trials evaluating Enbrel in the treatment of congestive heart failure (CHF) had been stopped after one of the trials revealed that Enbrel was suspected of causing CHF conditions to WORSEN in patients. Enbrel (the brand name for etenercept) was approved by the FDA in 1998 to treat rheumatoid arthritis. Taken by injection (self-administered by the patient), the drug's label warns that " allergic reactions to Enbrel are not uncommon. " These reactions include the risk of infections, swelling in the deep layers of the skin, and hives. Now you might wonder why a drug, already known to have side effects ranging from the annoying to the severe, would be given two large trials, to test it for an indication it wasn't even intended for. The simple answer: money. And lots of it. A month's round of Enbrel doses costs each patient a staggering $1,500. No surprise then that sales of Enbrel grossed $907 million in 2001 - an increase of nearly 18 percent over the previous year. So, again, no surprise that the manufacturers of Enbrel (a company named Immunex, in partnership with Wyeth), would make every attempt to expand the market for their bread-winner, in spite of the fact that the list of unpleasant side effects seems to grow as fast as the yearly revenue. ----------------------------- Loopholes & scams ----------------------------- And this is where Remicade comes in. Remicade (manufactured by Centocor, a subsidiary of Johnson & Johnson) is Enbrel's chief competitor. They were both approved by the FDA in 1998 to treat rheumatoid arthritis, they are both used to treat Crohn's disease (even though neither drug is approved for that), they have both been associated with disorders of the central nervous system (MS and Guillain-Barre syndrome), and now Enbrel joins Remicade in being known to worsen CHF symptoms. Remicade, however, has one huge advantage over Enbrel: Remicade has to be administered intravenously in a doctor's office. Ironically, this apparent drawback has turned into a plus, because Medicare reimburses doctors 95 percent of the " average wholesale price " for drugs that have to be administered by a doctor. So in spite of the inconvenience, Medicare recipients receive a huge break on the exorbitant price. But guess what? Centocor reps are now being investigated for possible fraud in exploiting this system. Some drug companies have boosted the Medicare reimbursements to physicians by inflating the average prices they report to the government. According to The New York Times, early last year Centocor posted a notice for physicians on its web site, detailing the " estimated revenue per patient " that doctors would reap by prescribing Remicade. It's easy to imagine how this sort of incentive might encourage a doctor to prescribe Remicade, before trying a low-cost generic drug called Methotrexate, which is also a standard treatment for rheumatoid arthritis. Add to that the fact that Medicare paid out more than $140 million for Remicade in 2001 (almost a 300 percent jump over the amount paid out in 2000), and you don't have to wonder why Centocor has drawn a federal investigation. ----------------------------- There's GOT to be a better way - and there is ----------------------------- Whew! That's a mighty tangled web of over-priced medications, dangerous side effects, and dubious drug company maneuvers. The good news is that the whole mess is avoidable for many who may find far less expensive relief from RA and Crohns's disease with two natural alternatives. At HSI, we've written extensively about therapies for both RA and Crohn's disease. In the February 2001 Members Alert newsletter, we told you about an oral supplement from Germany called Wobenzyme, a blend of pancreatic enzymes that clears the body of the excess antibodies that characterize an autoimmune disease. Studies have shown that Wobenzyme can prevent RA flare-ups and help lower levels of these antibodies, called circulating immune complexes. And in October 2000, we wrote about the therapeutic yeast saccharomyces boulardii (SB), which nourishes and protects the healthy intestinal flora. At least two clinical studies have shown that SB can significantly reduce Crohn's symptoms compared to placebo. If you or someone you care about has been prescribed Enbrel, Remicade, or even the lower-priced generic Methotrexate to treat RA or Crohn's disease, ask your health care provider about the natural alternatives before signing on for involved pharmaceutical procedures and their growing list of side effects. ************************************************************** ....and another thing Last week I bought a new portable compact disc player - the kind that plays CDs like a Walkman. While getting familiar with how it works, I came across this notice printed on the back of the unit: " This compact disc player meets all safety standards and regulations of the FCC, DHHS and FDA. " Huh? Why on earth would the Food and Drug Administration have regulations about a CD player? In the past I've given Consumer Reports magazine a hard time for dispensing half-baked advice on health care instead of doing what they're supposed to do: test and rate cars, kitchen appliances, and electronic devices like...well, like compact disc players! And now the FDA has regs for CD players!? Has the whole world gone mad!? This is as pure a case of over-regulation as you're likely to find. You would think that meeting all safety standards and regulations of the Federal Communications Commission and the Department of Health and Human Services would be more than enough. But no - they have to drag in the FDA as well? After enjoying a little rant about this at home (I gave my husband an earful) I settled down and did some research and found that apparently the FDA's role here has something to do with " radiation performance. " Hmmm. I wonder - would the radiation performance of a compact disc player come under the heading of " food " or " drug " ? To Your Good Health, Jenny Thompson Health Sciences Institute ************************************************************** Sources: " Enbrel Arthritis Drug May Worsen Heart Failure " Richard Woodman, Reuters Health, 1/8/03 " Arthritis Drug May Worsen Congestive Heart Failure " Dr. Joseph Mercola, Mercola.com " Methods Used for Marketing Arthritis Drug Are Under Fire " Melody Petersen, The New York Times, 4/11/02 Copyright ©1997-2003 by www.hsibaltimore.com, L.L.C. The e-Alert may not be posted on commercial sites without written permission. ************************************************************** ************************************************************** If you'd like to participate in the HSI Forum, search past e-Alerts and products or you're an HSI member and would like to search past articles, visit http://www.hsibaltimore.com ************************************************************** To learn more about HSI, call (508) 368-7494 or visit http://www.agora-inc.com/reports/HSI/WHSIC313/home.cfm. ************************************************************** Gettingwell- / Vitamins, Herbs, Aminos, etc. To , e-mail to: Gettingwell- Or, go to our group site: Gettingwell Mail Plus - Powerful. Affordable. Sign up now Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.